This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order ...

Novo Nordisk agreed to pay up to $2 billion for the rights to a developmental weight-loss and obesity drug from Chinese ...

Novo Nordisk announced Monday a $2 billion deal with a Chinese company making a drug in the same GLP-1 space where the Danish company is currently the leading player. Novo Nordisk said it’s ...

Eliteindekset lukkede i en stigning på 0,7 pct., og bedst gik det for den danske medicinalkæmpe Novo Nordisk, der lukkede 2,8 pct. højere Investeringsøkonom i Nordnet, Per Hansen, har fra ...

Novo Nordisk , the producer of Ozempic, Wegovy and other medications, will invest 6.4 billion reais ($1.09 billion) in Brazil ...

Novo Nordisk has signed an exclusive global licensing deal worth up to $2 billion for UBT251, a weight-loss drug developed by China-based The United Laboratories International Holdings Limited.

Novo Nordisk A/S Bagsværd, Denmark, 3 April 2025 – Novo Nordisk today announced the following changes in Executive Management. After a distinguished career of 28 years with Novo Nordisk, hereof ...

Nearly one in three adults with type 2 diabetes have CVD. Novo Nordisk continues to evolve its focus beyond diabetes and obesity towards a broader spectrum of metabolic and cardiovascular health ...

Europe’s largest pharmaceutical firm, Novo Nordisk, saw its stocks tumble 27% in March, marking their worst monthly performance since July 2002. As of market close on 31 March, the Danish firm ...

Danish pharmaceutical company Novo Nordisk — best known for its blockbuster weight-loss drugs Ozempic and Wegovy — has signed a $2 billion deal to acquire the global rights to an experimental ...

Bagsværd, Denmark, 10 March 2025 – Today, Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme. REDEFINE 2 is a 68-week efficacy and safety trial ...

Also Read: Novo Nordisk To Pay Around $2 Billion For Obesity Drug From China-Based Biotech The trial also demonstrated superiority to placebo for all confirmatory secondary outcomes assessed ...